Philogen S.p.a.
Clinical trials sponsored by Philogen S.p.a., explained in plain language.
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new drug combination (L19IL2 plus ruxolitinib) in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 partici…
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New injection combo takes aim at tough skin cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of two immune-boosting drugs, L19IL2 and L19TNF, injected directly into skin tumors. It is for people with advanced cutaneous squamous cell carcinoma whose cancer has worsened despite or who cannot tolerate standard immunotherapy. Up to 92 p…
Phase: PHASE2 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New injection shows promise for Tough-to-Treat skin cancer
Disease control Not yet recruitingThis phase 2 trial tests a new drug combination, L19IL2/L19TNF, injected directly into skin tumors. It is for people with advanced basal cell carcinoma that has worsened despite or cannot tolerate standard treatments. The study will enroll 92 participants and track how many respo…
Phase: PHASE2 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC